NCT06879379View on ClinicalTrials.gov

KPD Consolidation After ASCT in NDMM Patients

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

202

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

March 31, 2028

Study Completion Date

March 31, 2029

Conditions
Multiple Myeloma, Newly Diagnosed
Interventions
DRUG

KPD (carfilzomib, pomalidomide, and dexamethasone) consolidation

After post-transplant randomization, patients will receive either KPD (carfilzomib, pomalidomide, and dexamethasone) consolidation then maintenance or no consolidation and maintenance.

Trial Locations (3)

100044

RECRUITING

Peking University People's Hospital, Beijing

100045

RECRUITING

Fuxing Hospital affiliated to Capital Medical University, Beijing

021

RECRUITING

Shanghai Changzheng Hospital, Shanghai

All Listed Sponsors
lead

Peking University People's Hospital

OTHER